"Seeing A Cure"

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes.

Our focus is on developing and commercializing effective new diagnostic and therapeutic radiopharmaceuticals for metastatic cancer. Using the radioisotope fluorine-18 (atomic number 9) we can precisely image cancers and determine if they have metastasized. Guided by PET imaging to see a patient’s cancer, the same molecules can be used to treat it.

By attaching a therapeutic radioisotope such as Actinium-225 (an alpha emitter) we selectively treat each cancer site, while sparing normal organs, to improve the outcome of cancer patients. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the life of patients affected by metastatic cancers.

“What’s In A Name”

“Alpha-9” combines our approach of using superior Alpha emitters for therapy, with “9” the atomic number for fluorine, the choice isotope for PET imaging made possible with our “boron-tag” technology.

We are applying our proprietary technologies to design molecules that harness the power of radioactivity to better image and directly deliver radiotherapy to cancer cells. We combine powerful, non-invasive, positron emission tomographic (PET) imaging with targeted radiotherapy for precision cancer treatments. By using imaging to "see" a patient's cancer, we use the same approach to precisely deliver therapeutic radioisotopes to tumour sites.

Our scientific founders are leaders in nuclear medicine, radiochemistry, and synthetic chemistry with over 60 years combined experience in the design of new radiotheranostics. With this multidisciplinary know-how, we are bringing forward novel products for cancer imaging and treatment.